Drawing down on work licensed from Washington Univesity, Fimbrion is organized around the discovery, development and commercialization pf antimicrobial-sparing, first-in-class antivirulence drugs for the prevention and treatment of infectious diseases caused by bacteria, including antibiotic-resistant strains. Pre-dating the firm's SBIR involvement, Fimbrion Therapeutic's management had put into place working relationship with GSK to work on development of a small-molecule drug for treatment and prevention of urinary tract infections
